[en] The genomic profile of multiple myeloma (MM) has prognostic value by dividing patients into a good
prognosis hyperdiploid group and a bad prognosis non-hyperdiploid group with a higher incidence of
IgH translocations. This classification, however, is inadequate and many other parameters like
mutations, epigenetic modifications and genomic heterogeneity may influence the prognosis. We
performed a genomic study by array-based comparative genomic hybridization (aCGH) on a cohort of
162 patients to evaluate the frequency of genomic gains and losses. We identified a high frequency of
X chromosome alterations leading to partial Xq duplication, often associated with Xi deletion in
female patients. This partial X duplication could be a cytogenetic marker of aneuploidy as it is
correlated with a high number of chromosomal breakages. Patient with high level of chromosomal
breakage had reduced survival regardless the region implicated. A higher transcriptional level was
shown for genes with potential implication in cancer and located in this altered region. Among these
genes, IKBKG and IRAK1 are members of the NFKB pathway which plays an important role in MM
and is a target for specific treatments.
Research Center/Unit :
University of Liège, GIGA-Research, Laboratory of Human Genetics, Liège, Belgium
Disciplines :
Oncology
Author, co-author :
Sticca, Tiberio ; Université de Liège > Département des sciences biomédicales et précliniques > GIGA-R : Génétique humaine
CABERG, Jean-Hubert ; Centre Hospitalier Universitaire de Liège - CHU > Service de génétique
Wenric, Stéphane ; Université de Liège > Département des sciences cliniques > Oncologie
Poulet, Christophe ; Université de Liège > Département des sciences biomédicales et précliniques > GIGA-R : Génétique humaine
HERENS, Christian ; Centre Hospitalier Universitaire de Liège - CHU > Service de génétique
JAMAR, Mauricette ; Centre Hospitalier Universitaire de Liège - CHU > Service de génétique
Josse, Claire ; Université de Liège > Département des sciences biomédicales et précliniques > GIGA-R : Génétique humaine
El Guendi, Sonia ; Université de Liège > Département des sciences biomédicales et précliniques > GIGA-R : Génétique humaine
MAX, Stéphanie ; Centre Hospitalier Universitaire de Liège - CHU > Service d'oncologie médicale
BEGUIN, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Service d'hématologie clinique
GOTHOT, André ; Centre Hospitalier Universitaire de Liège - CHU > Service d'hématologie biologique et immuno-hématologie
CAERS, Jo ; Centre Hospitalier Universitaire de Liège - CHU > Service d'hématologie clinique
Bours, Vincent ; Université de Liège > Département des sciences biomédicales et précliniques > GIGA-R : Génétique humaine
Genomic Studies of Multiple Myeloma Reveal an Association between X Chromosome Alterations and Genomic Profile Complexity.
Publication date :
2017
Journal title :
Genes, Chromosomes and Cancer
ISSN :
1045-2257
eISSN :
1098-2264
Publisher :
Wiley Liss, Inc., New York, United States - New York
Volume :
56
Pages :
18-27
Peer reviewed :
Peer Reviewed verified by ORBi
Name of the research project :
Intérêt des technologies haut débit pour l’évaluation pronostique des altérations génomiques dans le myélome multiple
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique Fonds Léon Fredericq CAC - Centre anticancéreux près l'Université de Liège asbl Fonds d'Investissement à la Recherche scientifique (CHU, Liège) ULiège FSR - Université de Liège. Fonds spéciaux pour la recherche Région wallonne
Adamson B, Smogorzewska A, Sigoillot FD, King RW, Elledge SJ. 2012. A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA damage response. Nat Cell Biol 14:318–328.
Aigelsreiter A, Haybaeck J, Schauer S, Kiesslich T, Bettermann K, Griessbacher A, Stojakovic T, Bauernhofer T, Samonigg H, Kornprat P, Lackner C, Pichler M. 2012. NEMO expression in human hepatocellular carcinoma and its association with clinical outcome. Hum Pathol 43:1012–1019.
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho Y-J, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao M-S, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463:899–905.
Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JMC, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai Y-T, Shammas M, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC. 2014. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:2997–2997.
Broyl A, Hose D, Lokhorst H, Knegt YD, Peeters J, Jauch A, Bertsch U, Buijs A, Stevens-kroef M, Beverloo HB, Vellenga E, Zweegman S, Holt BVD, Jarari L, Mulligan G, Goldschmidt H, Duin MV, Sonneveld P. 2010. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Gene Exp 116:2543–2553.
Cagnetta A, Lovera D, Grasso R, Colombo N, Canepa L, Ballerini F, Calvio M, Miglino M, Gobbi M, Lemoli R, Cea M. 2015. Mechanisms and clinical applications of genome instability in multiple myeloma. BioMed Res Int 2015:1–8.
Chaligné R, Popova T, Mendoza-Parra M-A, Saleem M-AM, Gentien D, Ban K, Piolot T, Leroy O, Mariani O, Gronemeyer H, Vincent-Salomon A, Stern M-h, Heard E. 2015. The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer. Genome Res 25:488–503.
Chapman M, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet J-P, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart K, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway L, Meyerson M, Lander ES, Getz G, Golub TR. 2011. Initial genome sequencing and analysis of multiple myeloma. Nature 471:467–472.
Chung TH, Mulligan G, Fonseca R, Chng WJ. 2013. A novel measure of chromosome instability can account for prognostic difference in multiple myeloma. PLoS One 8:1–8:
de Carvalho F, Vettore AL, Colleoni GWB. 2012. Cancer/testis antigen MAGE-C1/CT7: New target for multiple myeloma therapy. Clin Dev Immunol 2012:1–7.
Gronseth CM, McElhone SE, Storer BE, Kroeger K, Sandhu V, Fero ML, Appelbaum FR, Estey EH, Fang M. 2015. Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia. Cancer 121:2900–2908.
Herrero AB, San Miguel J, Gutierrez NC. 2015. Deregulation of DNA double-strand break repair in multiple myeloma: Implications for genome stability. PLoS One 10:e0121581–e0121581.
Jäger N, Schlesner M, Jones DTW, Raffel S, Mallm J-P, Junge KM, Weichenhan D, Bauer T, Ishaque N, Kool M, Northcott PA, Korshunov A, Drews RM, Koster J, Versteeg R, Richter J, Hummel M, Mack SC, Taylor MD, Witt H, Swartman B, Schulte-Bockholt D, Sultan M, Yaspo M-L, Lehrach H, Hutter B, Brors B, Wolf S, Plass C, Siebert R, Trumpp A, Rippe K, Lehmann I, Lichter P, Pfister SM, Eils R. 2013. Hypermutation of the inactive X chromosome is a frequent event in cancer. Cell 155:567–581.
Kang J, Lee HJ, Kim J, Lee JJ, Maeng L-s. 2015. Dysregulation of X chromosome inactivation in high grade ovarian serous adenocarcinoma. PLoS One 10:e0118927–e0118927.
Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL. 2012. Clonal competition with alternating dominance in multiple myeloma. Blood 120:1067–1076.
Krem MM, Press OW, Horwitz MS, Tidwell T. 2015. Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy. Br J Haematol 171:13–28.
Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, Greenberg A, Russell SJ, Zeldenrust SR, Lust JA, Kyle RA, Bergsagel L, Rajkumar SV. 2012. Trisomies in multiple myeloma: Impact on survival in patients with high-risk cytogenetics. Blood 119:2100–2105.
Lose F, Duffy DL, Kay GF, Kedda M, Spurdle AB. 2008. Skewed X chromosome inactivation and breast and ovarian cancer status: Evidence for X-linked modifiers of BRCA1. J Natl Cancer Inst 100:1519–1529.
Munshi NC, Avet-Loiseau H. 2011. Genomics in multiple myeloma. Clin Cancer Res 17:1234–1242.
Przybytkowski E, Lenkiewicz E, Barrett MT, Klein K, Nabavi S, Greenwood CMT, Basik M. 2014. Chromosome-breakage genomic instability and chromothripsis in breast cancer. BMC Genomics 15:579–579.
Rashid NU, Sperling S, Bolli N, Wedge DC, Van Loo P, Tai YT, Shammas M, Fulciniti M, Samur MK, Richardson PG, Magrangeas F, Minvielle S, Futreal P, Anderson KC, Avet-Loiseau H, Campbell PJ, Parmigiani G, Munshi NC. 2014. Differential and limited expression of mutant alleles in multiple myeloma. Blood 124:3110–3117.
Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. 2006. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9:121–132.
Sankaranarayanan P, Schomay TE, Aiello KA, Alter O. 2015. Tensor GSVD of patient and platform-matched tumor and normal DNA copy-number profiles uncovers chromosome arm-wide patterns of tumor-exclusive platform-consistent alterations encoding for cell transformation and predicting ovarian cancer survival. PLoS One 10:e0121396–e0121396.
Sirchia SM, Ramoscelli L, Grati FR, Barbera F, Coradini D, Rossella F, Porta G, Lesma E, Ruggeri A, Radice P, Simoni G, Miozzo M. 2005. Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells. Cancer Res 65:2139–2146.
Smadja NV. 2001. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98:2229–2238.
Sun Z, Prodduturi N, Sun SY, Thompson EA, Kocher J-PA. 2015. Chromosome X genomic and epigenomic aberrations and clinical implications in breast cancer by base resolution profiling. Epigenomics 7:1099–1110.
Walker BA, Morgan GJ. 2006. Use of single nucleotide polymorphism-based mapping arrays to detect copy number changes and loss of heterozygosity in multiple myeloma. Clin Lymphoma Myeloma 7:186–192.
Wang H-M, Chuang S-M, Su Y-C, Li Y-H, Chueh PJ. 2011. Down-regulation of tumor-associated NADH oxidase, tNOX (ENOX2), enhances capsaicin-induced inhibition of gastric cancer cell growth. Cell Biochem Biophys 61:355–366.
Wee ZN, Yatim SMJM, Kohlbauer VK, Feng M, Goh JY, Yi B, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DSB, Tan EY, Yu Q. 2015. IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat Commun 6:8746–8746.
Zeng Z-M, Chuang S-M, Chang T-C, Hong C-W, Chou J-C, Yang J-J, Chueh PJ. 2012. Phosphorylation of serine-504 of tNOX (ENOX2) modulates cell proliferation and migration in cancer cells. Exp Cell Res 318:1759–1766.
